In a welcome move, Albemarle saw its Relative Strength Rating rise from 61 to 73 on Thursday.
Can You Really Time The Stock Market?
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Albemarle can continue to show renewed price strength and clear that threshold.
Albemarle is not currently near a potential buying area. See if the stock goes on to form a base that could kick off a new climb.
Earnings grew 175% last quarter, up from 0% in the prior report. Revenue also increased, from -21% to -7%.
Albemarle holds the No. 14 rank among its peers in the Chemicals-Specialty industry group. Perimeter Solutions, Niagen Bioscience and Solaris Energy Infr are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
